 4. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered i.e., Grade 1 or at baseline from adverse events due to a previously administered agent. Subjects with Grade 2 neuropathy are an exception to this criterion and may qualify for the study. 